According to Kaisai Biotech's announcement, as of the date the inspection opinion was issued, the number of shares in the company's special securities account was 1.2 million shares, accounting for 0.17% of the total share capital. According to regulations, shares that have already been repurchased do not enjoy rights such as profit distribution, etc., so differentiated dividends will be implemented in 2025. The company's 2025 annual shareholders' meeting reviewed and approved the profit distribution plan. A cash dividend of 4.50 yuan will be distributed to all shareholders for every 10 shares based on the total share capital minus the repurchase of shares in the special account. It is proposed to distribute a cash dividend of 324 million yuan for every 10 shares without bonus shares or share capital transfers. Based on the closing price on July 2, 2026, differentiated equity distribution has little impact on the exclusion and dividend reference price.

According to Kaisai Biotech's announcement, as of the date the inspection opinion was issued, the number of shares in the company's special securities account was 1.2 million shares, accounting for 0.17% of the total share capital. According to regulations, shares that have already been repurchased do not enjoy rights such as profit distribution, etc., so differentiated dividends will be implemented in 2025. The company's 2025 annual shareholders' meeting reviewed and approved the profit distribution plan. A cash dividend of 4.50 yuan will be distributed to all shareholders for every 10 shares based on the total share capital minus the repurchase of shares in the special account. It is proposed to distribute a cash dividend of 324 million yuan for every 10 shares without bonus shares or share capital transfers. Based on the closing price on July 2, 2026, differentiated equity distribution has little impact on the exclusion and dividend reference price.